Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: Review and meta-analysis

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 225-231

  Wang, Jing ^a   Shi, Qiong ^a   Yuan, Tai xian ^a   Song, Qi lin ^a   Zhang, Yan ^a   Wei, Qiang ^a   Zhou, Lan ^a   Luo, Jinyong ^a   Zuo, Guowei ^a   Tang, Min ^a   He, Tong Chuan ^a,b   Weng, Yaguang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Meta analysis; MMP 9; Osteosarcoma

Indexed keywords

GELATINASE B; TUMOR MARKER;

ANIMAL; ENZYMOLOGY; HUMAN; META ANALYSIS; METABOLISM; OSTEOSARCOMA; PATHOLOGY;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASE 9; OSTEOSARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84898623549     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.023     Document Type: Review

References (50)

1. Ta H.T., Dass C.R., Choong P.F., Dunstan D.E. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009, 28:247-263.
2. Ritter J., Bielack S. Osteosarcoma. Ann Oncol 2010, 21:vii320-vii325.
3. Geller D.S., Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010, 8:705-718.
4. Federman N., Bernthal N., Eilber F.C., Tap W.D. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 2009, 10:82-93.
5. Bielack S., Carrle D., Casali P. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:137-139.
6. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297.
7. Hadler-Olsen E., Winberg J.-O., Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013, 34:2041-2051.
8. Hurst N., Stocken D., Wilson S., Keh C., Wakelam M., Ismail T. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007, 97:971-977.
9. Eissa S., Ali-Labib R., Swellam M., Bassiony M., Tash F., El-Zayat T.M. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 2007, 52:1388-1397.
10. Roy R., Louis G., Loughlin K.R., et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008, 14:6610-6617.
11. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:1-13.
12. Whiting P.F., Weswood M.E., Rutjes A.W., Reitsma J.B., Bossuyt P.N., Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006, 6:9.
13. Dwamena B.A. Midas: a program for meta-analytical integration of diagnostic accuracy studies in Stata 2007, Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School.
14. Chu H., Cole S.R. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006, 59:1331-1332.
15. Van Houwelingen H.C., Zwinderman K.H., Stijnen T. A bivariate approach to meta-analysis. Stat Med 1993, 12:2273-2284.
16. Van Houwelingen H.C., Arends L.R., Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002, 21:589-624.
17. Chen L., Lin J., Zhang S. Expression and clinical significance of MMP-9 in osteosarcoma. Zhongguo Zhongliu Linchuang 2001, 28:431-433.
18. Peng T.S., Qiu J.S., Wu H.X., Liang H.Z., Luo C.Q. Expressions of CD44s, MMP-9, and Ki-67: possible association with invasion, metastasis, and recurrence of osteosarcoma. Ai zheng = Aizheng = Chin J Cancer 2002, 21:745-750.
19. Huang Z., Yang S., Liu Y., Li J. The expressions of u-PA, MMP-9 in osteosarcoma and their significance. Cen China Med J 2005, 110-111.
20. Li X.-D., Wang W.-C., Wang Y. Expression and clinical significance of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in osteosarcoma. Chin J Misdiagn 2005, 423-425.
21. Li Y., Xiao Y., Yu L., Cheng Z. Expressions of MMP-2, MMP-9 and NF-κB in osteosarcoma and their relativity significance. Appl J, Gen Pract 2006, 255-257.
22. Luo X.-Z., Ni J.-D. Expression and clinical significance of MMP-9 and PCNA in osteosarcoma. J Clin Res 2006, 682-684.
23. Liu Y.-M., Wu H.-H., Cheng G., He Y.-F., Li X.-N. Expressions of MMP-9, TIMP-1 and CD44 in osteosarcoma. Med J Natl Def Forces Northwest China 2007, 427-428.
24. Zang J., Wang Y., Wang J. Expression and clinical significance of CDl47 and MMP-9 in osteosarcoma. Cent Plains Med J 2007, 34:3-5.
25. Lei L., Lv Z., Han P.-F., Zhang Y. Expression of PTEN and MMP-9 in osteosarcoma and its clinical significance. J Shanxi Med Univ 2009, 219:221-287.
26. Liao H., Feng X.-R., Mao X.-F. Relationships between expressions of COX-2, MMP-9 and tumor microvessel density in patients with osteosarcoma. Med J Natl Def Forces Southwest China 2009, 377-379.
27. Lu Y.-S., Jin Y., Liu G.-Y., Gao Z.-L. Expression of MMP-9 and TIMP-1 and their diagnostic significance in high risk osteosarcoma. Chin J Lab Diagn 2009, 464-465.
28. Zhou Q., Liu A. Expression and clinical significance of MMP-9 in osteosarcoma. China Pract Med 2009, 120-121.
29. Du H.-Z., Liu X.-M., Zhang Y.-X., Song W.-G. Expression of RhoC and MMP-9 in osteosarcoma and its clinic pathological significance. Mod, Prev Med 2010, 1794:1795-1797.
30. Ji X. Expression and clinical significance of survivin and MMP-9 in osteosarcoma. China Mod Dr 2010, 72-73.
31. Xu X.-Z., Huang G., Liu J.-F., Li L.-Q., Luo Y. Expression of PTEN, COX-2 and MMP-9 in osteosarcoma and its clinical significance. J Clin Res 2010, 27:820-823.
32. Wang J., Liu Y.J., Zhao D., Shan Y.X. Expressions of MMP-9 and PCNA in telomerase and alternative lengthening of telomere osteosarcoma and their clinical significances. J Jilin Univ Med Ed 2011, 37:495-498.
33. Lian H., Li Y., Zhao M., Liu R. Expression of COX-2, MMP-9 in osteosarcoma and their clinical significance. Hebei J TCM 2013, 1105-1107.
34. Meng X.-W., Yan H.-N., Zhu M., Liu X., Gao L.-Y., Qiu W. Expressions of nuclear factor, matrix metalloproteinase-9 and cyclooxygenase-2 in osteosarcoma and their relationship with angiogenesis. J Bengbu Med Coll 2013, 270-272.
35. Enneking W.F. A system of staging musculoskeletal neoplasms. Instr Course Lect 1988, 37:3-10.
36. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
37. Van den Steen P., Dubois B., Nelissen I., Rudd P., Dwek R., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
38. Moss L.A.S., Jensen-Taubman S., Stetler-Stevenson W.G. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012, 181:1895-1899.
39. Provatopoulou X., Gounaris A., Kalogera E., et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9:390.
40. Patel S., Sumitra G., Koner B., Saxena A. Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression. Clin Biochem 2011, 44:869-872.
41. Fernández C., Yan L., Louis G., Yang J., Kutok J., Moses M. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11:5390-5395.
42. Incorvaia L., Badalamenti G., Rini G., et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007, 27:1519-1525.
43. Mroczko B., Kozłowski M., Groblewska M., et al. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta 2008, 389:61-66.
44. Mroczko B., Lukaszewicz-Zajac M., Wereszczynska-Siemiatkowska U., et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009, 38:613-618.
45. Shpitzer T., Hamzany Y., Bahar G., et al. Salivary analysis of oral cancer biomarkers. Br J Cancer 2009, 101:1194-1198.
46. Smith E., Zurakowski D., Saad A., Scott R., Moses M. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008, 14:2378-2386.
47. Glas A.S., Lijmer J.G., Prins M.H., Bonsel G.J., Bossuyt P.M. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56:1129-1135.
48. Rosman A., Korsten M. Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing. Adv Med Sci 2007, 52:76-82.
49. Walter S. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002, 21:1237-1256.
50. Jones C.M., Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 2005, 79:16-20.